Latest Period
Q1 2026
Security Snapshot
Apogee Therapeutics, Inc. - COMMON STOCK (APGE) Institutional Ownership
CUSIP: 03770N101
13F Institutional Holders and Ownership History from Q3 2023 to Q1 2026
Institutions Reporting
222
Shares (Excl. Options)
79,061,115
Price
$84.17
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / COMMON STOCK
- Symbol
- APGE on Nasdaq
- Shares outstanding
- 61,257,262
- Price per share
- $82.03
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 79,061,115
- Total reported value
- $6,638,906,729
- % of total 13F portfolios
- 0.01%
- Share change
- +8,638,668
- Value change
- +$743,266,174
- Number of holders
- 222
- Price from insider filings
- $82.03
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- APGE - Apogee Therapeutics, Inc. - COMMON STOCK is tracked under CUSIP 03770N101.
- 222 institutions reported positions in Q1 2026.
- 7 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 206 to 222 between Q4 2025 and Q1 2026.
- Reported value moved from $5,266,434,045 to $6,638,906,729.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 222 institutions filings for Q1 2026.
Security key
03770N101
Latest holder period
Q1 2026
13F holders
222
13D/G owners
7
CIK / CUSIP context first
Open Q1 2026 holders
APGE full holder history
Apogee Therapeutics, Inc. SEC filings
Apogee Therapeutics, Inc. company facts
Apogee Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 03770N101:
Significant Owners of Apogee Therapeutics, Inc. - COMMON STOCK (APGE) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 17% | +50% | $866,203,754 | +$343,190,907 | 10,291,220 | +66% | T. Rowe Price Investment Management, Inc. | 31 Mar 2026 |
| FMR LLC | 15% | $266,406,847 | 6,907,100 | FMR LLC | 30 Jun 2025 | |||
| Fairmount Funds Management LLC | 10% | 0% | $482,139,697 | +$51,168,083 | 6,764,974 | +12% | Peter Evan Harwin | 26 Mar 2026 |
| WELLINGTON MANAGEMENT GROUP LLP | 8.7% | -17% | $374,980,215 | -$10,946,319 | 4,746,585 | -2.8% | Wellington Management Group LLP | 31 Dec 2025 |
| RTW INVESTMENTS, LP | 4.9% | -18% | $214,255,663 | 2,712,097 | 0% | RTW Investments, LP | 31 Dec 2025 | |
| BlackRock, Inc. | 5.5% | $109,396,539 | 2,518,725 | BlackRock, Inc. | 30 Jun 2025 | |||
| DRIEHAUS CAPITAL MANAGEMENT LLC | 4.7% | $85,757,284 | 2,158,502 | DRIEHAUS CAPITAL MANAGEMENT LLC | 30 Sep 2025 |
As of 31 Mar 2026, 222 institutional investors reported holding 79,061,115 shares of Apogee Therapeutics, Inc. - COMMON STOCK (APGE). This represents 129% of the company’s total 61,257,262 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Apogee Therapeutics, Inc. - COMMON STOCK (APGE) together control 104% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 17% | 10,300,984 | +277% | 0.6% | $867,034,000 |
| FMR LLC | 15% | 9,262,291 | +13% | 0.04% | $779,606,994 |
| Venrock Adviser, LLC | 14% | 8,493,321 | 0% | 27% | $714,882,829 |
| WELLINGTON MANAGEMENT GROUP LLP | 7.1% | 4,375,703 | -7.8% | 0.07% | $368,302,921 |
| BlackRock, Inc. | 6.7% | 4,085,651 | +8% | 0.01% | $343,889,202 |
| RTW INVESTMENTS, LP | 4.5% | 2,782,097 | +2.6% | 2.3% | $234,169,104 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.1% | 2,502,095 | 0% | 0.01% | $210,601,336 |
| JANUS HENDERSON GROUP PLC | 3.9% | 2,360,596 | +14% | 0.09% | $198,808,884 |
| STATE STREET CORP | 3.5% | 2,162,964 | +28% | 0.01% | $182,056,680 |
| Driehaus Capital Management LLC | 3.1% | 1,920,800 | -12% | 1.2% | $161,673,736 |
| PERCEPTIVE ADVISORS LLC | 2.5% | 1,540,384 | -34% | 2.6% | $129,654,121 |
| Paradigm Biocapital Advisors LP | 2.2% | 1,348,243 | +20% | 2.3% | $113,481,613 |
| Affinity Asset Advisors, LLC | 2.1% | 1,284,926 | +4% | 6.3% | $108,152,221 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 1,217,289 | +15% | 0.01% | $102,483,956 |
| UBS Group AG | 1.9% | 1,144,328 | +17% | 0.02% | $96,318,088 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.9% | 1,143,152 | -7.6% | 0.01% | $96,221,000 |
| JPMORGAN CHASE & CO | 1.8% | 1,110,470 | -19% | 0.01% | $87,416,200 |
| Vestal Point Capital, LP | 1.8% | 1,100,000 | +100% | 2.6% | $92,587,000 |
| FRONTIER CAPITAL MANAGEMENT CO LLC | 1.7% | 1,064,483 | +122% | 0.92% | $89,597,516 |
| ALLIANCEBERNSTEIN L.P. | 1.6% | 990,297 | -9.5% | 0.02% | $74,747,618 |
| BANK OF AMERICA CORP /DE/ | 1.5% | 900,871 | +14% | 0.01% | $75,826,311 |
| MERCER GLOBAL ADVISORS INC /ADV | 1.4% | 831,428 | -6.7% | 0.1% | $69,981,295 |
| GOLDMAN SACHS GROUP INC | 1.1% | 652,590 | +15% | 0.01% | $54,928,500 |
| CITADEL ADVISORS LLC | 0.98% | 598,902 | -22% | 0.04% | $50,409,581 |
| MORGAN STANLEY | 0.97% | 595,032 | -33% | 0% | $50,083,937 |
Institutional Holders of Apogee Therapeutics, Inc. - COMMON STOCK (APGE) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 79,061,115 | $6,638,906,729 | +$743,266,174 | $84.17 | 222 |
| 2025 Q4 | 69,771,331 | $5,266,434,045 | +$762,006,154 | $75.48 | 206 |
| 2025 Q3 | 59,584,020 | $2,367,665,644 | +$56,487,603 | $39.73 | 173 |
| 2025 Q2 | 57,837,483 | $2,511,890,310 | -$147,322,983 | $43.43 | 180 |
| 2025 Q1 | 61,488,037 | $2,301,755,351 | +$131,273,115 | $37.36 | 165 |
| 2024 Q4 | 57,873,775 | $2,621,627,227 | +$63,332,544 | $45.30 | 156 |
| 2024 Q3 | 56,092,373 | $3,292,239,932 | +$134,148,823 | $58.74 | 137 |
| 2024 Q2 | 54,152,101 | $2,130,892,019 | -$9,800,456 | $39.35 | 137 |
| 2024 Q1 | 52,915,146 | $3,516,219,943 | +$778,331,224 | $66.45 | 137 |
| 2023 Q4 | 41,768,396 | $1,163,676,392 | +$48,111,524 | $27.94 | 85 |
| 2023 Q3 | 40,111,211 | $848,653,526 | +$848,653,497 | $21.30 | 73 |